As the OLP cases in our study showed a high IL-23R expression and IL-23 inhibitors are clinically available (27), the potential role of anti-IL-23 therapy should be investigated in OLP and OL potentially malignant transforming oral lesions. The gene discussed is IL23R; the disease is oral lichen planus.